Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma

Authors: Qiqi Tao, Zhichao Lang, Yifei Li, Yuxiang Gao, Lifan Lin, Zhengping Yu, Jianjian Zheng, Suhui Yu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Necroptosis has been reported to be involved in cancer progression and associated with cancer prognosis. However, the prognostic values of necroptosis-related genes (NRGs) in hepatocellular carcinoma (HCC) remain largely unknown. This study aimed to build a signature on the basis of NRGs to evaluate the prognosis of HCC patients. In this study, using bioinformatic analyses of transcriptome sequencing data of HCC (n = 370) from The Cancer Genome Atlas (TCGA) database, 63 differentially expressed NRGs between HCC and adjacent normal tissues were determined. 24 differentially expressed NRGs were found to be related with overall survival (OS). Seven optimum NRGs, determined using Lasso regression and multivariate Cox regression analysis, were used to construct a new prognostic risk signature for predicting the prognosis of HCC patients. Then survival status scatter plots and survival curves demonstrated that the prognosis of patients with high-Riskscore was worse. The prognostic value of this 7-NRG signature was validated by the International Cancer Genome Consortium (ICGC) cohort and a local cohort (Wenzhou, China). Notably, Riskscore was defined as an independent risk factor for HCC prognosis using multivariate cox regression analysis. Immune infiltration analysis suggested that higher macrophage infiltration was found in patients in the high-risk group. Finally, enhanced 7 NRGs were found in HCC tissues by immunohistochemistry. In conclusion, a novel 7-NRG prognostic risk signature is generated, which contributes to the prediction in the prognosis of HCC patients for the clinicians.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
3.
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282–94.CrossRefPubMedPubMedCentral
4.
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in patients with Cirrhosis: a Meta-analysis. Gastroenterology. 2018;154(6):1706–1718e1701.CrossRefPubMed
5.
6.
Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, Krysko DV, Parys JB, Bultynck G, Vandenabeele P et al. Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells 2020, 9(8).
7.
Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100.CrossRefPubMedPubMedCentral
8.
Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki B, De Groote P, et al. Vaccination with Necroptotic Cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016;15(2):274–87.CrossRefPubMed
9.
Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 2016;5(6):e1149673.CrossRefPubMedPubMedCentral
10.
Feng X, Song Q, Yu A, Tang H, Peng Z, Wang X. Receptor-interacting protein kinase 3 is a predictor of survival and plays a Tumor suppressive role in Colorectal cancer. Neoplasma. 2015;62(4):592–601.CrossRefPubMed
11.
Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25(6):707–25.CrossRefPubMedPubMedCentral
12.
Nugues AL, El Bouazzati H, Hétuin D, Berthon C, Loyens A, Bertrand E, Jouy N, Idziorek T, Quesnel B. RIP3 is downregulated in human Myeloid Leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis. 2014;5(8):e1384.CrossRefPubMedPubMedCentral
13.
14.
15.
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–d551.CrossRefPubMed
16.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.CrossRefPubMedPubMedCentral
17.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.CrossRefPubMedPubMedCentral
18.
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.CrossRefPubMedPubMedCentral
19.
Zhou G, Li C, Zhang R, Zhan Y, Lin L, Lang Z, Tao Q, Zheng J. Kaempferol inhibits hepatic stellate cell activation by regulating miR-26b-5p/Jag1 Axis and Notch Pathway. Front Pharmacol. 2022;13:881855.CrossRefPubMedPubMedCentral
20.
Zhu K, Tao Q, Yan J, Lang Z, Li X, Li Y, Fan C, Yu Z. Machine learning identifies exosome features related to hepatocellular carcinoma. Front Cell Dev Biol. 2022;10:1020415.CrossRefPubMedPubMedCentral
21.
Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, et al. Genomic Analysis of Vascular Invasion in HCC reveals Molecular drivers and predictive biomarkers. Hepatology. 2021;73(6):2342–60.CrossRefPubMed
22.
Feng J, Lu PZ, Zhu GZ, Hooi SC, Wu Y, Huang XW, Dai HQ, Chen PH, Li ZJ, Su WJ, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2021;42(1):160–70.CrossRefPubMed
23.
Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, Saenz de Viteri C, Fobar A, Parikh ND. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with Cirrhosis. Hepatology. 2022;75(3):541–9.CrossRefPubMed
24.
Seehawer M, Heinzmann F, D’Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, et al. Necroptosis microenvironment directs lineage commitment in Liver cancer. Nature. 2018;562(7725):69–75.CrossRefPubMedPubMedCentral
25.
El-Demiry SM, El-Yamany M, El-Gendy SM, Salem HA, Saber MM. Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. Life Sci. 2022;301:120594.CrossRefPubMed
26.
Xiang YK, Peng FH, Guo YQ, Ge H, Cai SY, Fan LX, Peng YX, Wen H, Wang Q, Tao L. Connexin32 activates necroptosis through src-mediated inhibition of caspase 8 in hepatocellular carcinoma. Cancer Sci. 2021;112(9):3507–19.CrossRefPubMedPubMedCentral
27.
Chen X, Cheng B, Dai D, Wu Y, Feng Z, Tong C, Wang X, Zhao J. Heparanase induces necroptosis of microvascular endothelial cells to promote the Metastasis of hepatocellular carcinoma. Cell Death Discov. 2021;7(1):33.CrossRefPubMedPubMedCentral
28.
Wang S, Wu Q, Chen T, Su R, Pan C, Qian J, Huang H, Yin S, Xie H, Zhou L et al. Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model. J Hepatol 2022.
29.
Sun H, Huang Q, Huang M, Wen H, Lin R, Zheng M, Qu K, Li K, Wei H, Xiao W, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168–83.CrossRefPubMed
30.
Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.CrossRefPubMedPubMedCentral
31.
Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, et al. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J Cancer. 2019;144(10):2613–24.CrossRefPubMed
32.
Wei W, Liu M, Ning S, Wei J, Zhong J, Li J, Cai Z, Zhang L. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer. 2020;20(1):6.CrossRefPubMedPubMedCentral
33.
Zhou Y, Deng X, Zang N, Li H, Li G, Li C, He M. Transcriptomic and proteomic investigation of HSP90A as a potential biomarker for HCC. Med Sci Monit. 2015;21:4039–49.CrossRefPubMedPubMedCentral
34.
Gu Y, Wang C, Chen S, Tang J, Guo X, Hu W, Cui A, Zhang D, Yu K, Chen M. A critical role of Peptidylprolyl isomerase A pseudogene 22/microRNA-197-3p/Peptidylprolyl isomerase a Axis in Hepatocellular Carcinoma. Front Genet. 2021;12:604461.CrossRefPubMedPubMedCentral
35.
Cheng J, Qian D, Ding X, Song T, Cai M, Dan X, Wang Y, Zhao J, Liu Z, Wu Z, et al. High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients. Cell Death Dis. 2018;9(10):991.CrossRefPubMedPubMedCentral
36.
37.
Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T, et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016;7:12030.CrossRefPubMedPubMedCentral
38.
Zhao Z, Liu H, Zhou X, Fang D, Ou X, Ye J, Peng J, Xu J. Necroptosis-related lncRNAs: Predicting Prognosis and the distinction between the Cold and Hot tumors in gastric Cancer. J Oncol. 2021;2021:6718443.CrossRefPubMedPubMedCentral
39.
Ren H, Zheng J, Cheng Q, Yang X, Fu Q. Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma. Front Genet. 2022;13:900713.CrossRefPubMedPubMedCentral
Metadata
Title
Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma
Authors
Qiqi Tao
Zhichao Lang
Yifei Li
Yuxiang Gao
Lifan Lin
Zhengping Yu
Jianjian Zheng
Suhui Yu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11521-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study

Research

Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer

Study protocol

Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study – (NCT05103020) – study protocol

Research

Valero’s host index is useful in predicting radiation-induced trismus and osteoradionecrosis of the jaw risks in locally advanced nasopharyngeal carcinoma patients

Correction

Correction to: DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells

Research

Tissue proteome analysis for profiling proteins associated with lymph node metastasis in gallbladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits